{"version":"1.0","provider_name":"hollandbio","provider_url":"https:\/\/www.hollandbio.nl\/en\/","title":"Cytura Therapeutics to target genomic instability in cancer - hollandbio","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"hYVxvB3TiU\"><a href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/\">Cytura Therapeutics to target genomic instability in cancer<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/embed\/#?secret=hYVxvB3TiU\" width=\"600\" height=\"338\" title=\"&#8220;Cytura Therapeutics to target genomic instability in cancer&#8221; &#8212; hollandbio\" data-secret=\"hYVxvB3TiU\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.hollandbio.nl\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Cytura Therapeutics has successfully closed a Seed financing round. The funding is provided by a syndicate led by Thuja Capital&nbsp; Healthcare (Seed) Fund II and includes BOM Brabant Ventures, the Centre for Drug Design and Discovery (CD3) \u2013 KU Leuven and the Gemma Frisius Fund. Cytura Therapeutics will use the new funding to advance its [&hellip;]","thumbnail_url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","thumbnail_width":1200,"thumbnail_height":675}